Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

BACKGROUND: Bictegravir (B)/emtricitabine (F)/tenofovir alafenamide (TAF) is guideline-recommended treatment for human immunodeficiency virus type 1 (HIV-1). We evaluated whether people receiving dolutegravir (DTG) plus F/TAF or F/TDF (tenofovir disoproxil fumarate) with viral suppression can switch...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Infect Dis
Glavni autori: Sax, Paul E, Rockstroh, Jürgen K, Luetkemeyer, Anne F, Yazdanpanah, Yazdan, Ward, Douglas, Trottier, Benoit, Rieger, Armin, Liu, Hui, Acosta, Rima, Collins, Sean E, Brainard, Diana M, Martin, Hal
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Online Only Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8282313/
https://ncbi.nlm.nih.gov/pubmed/32668455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciaa988
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items